{'fraction_non_alphanumeric': 0.029382957884427033, 'fraction_numerical': 0.007835455435847209, 'mean_word_length': 6.35251798561151, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Consolidation with alemtuzumab improves progression‐free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long‐term follow‐up of a randomized phase III trial of the German CLL Study Group (GCLLSG)

Alemtuzumab has shown considerable activity in untreated and relapsed chronic lymphocytic leukaemia. We report our long‐term experience in 21 patients within a randomized phase III trial investigating the role of alemtuzumab for consolidation therapy after first‐line fludarabine ± cyclophosphamide, which was stopped prematurely due to severe infections. However, after a median follow‐up of 48 months, progression‐free survival was significantly prolonged for patients receiving alemtuzumab consolidation compared to those with no further treatment (P = 0·004). Minimal residual disease (MRD) levels were persistently reduced after consolidation. Therefore, despite toxicity, MRD reduction by alemtuzumab consolidation translates into a significantly improved long‐term clinical outcome.